A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women.

Objective: To establish the effect on bone mineral density (BMD) of long-term (nine years) continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) and follow-up one year after discontinuation of ccHRT.

Study Design: A total of 279 women were treated with daily dosages of E(2)V + MPA: 1 mg + 2.5 mg (n = 69), 1 mg + 5 mg (n = 70) or 2 mg + 5 mg (n = 140) (Indivina), Orion Pharma, Espoo, Finland) for 8.

A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings.

Objective: To assess the safety and health-related quality of life (HRQOL) of continuous combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) over nine years and at follow-up one year after discontinuation.

Study Design: A total of 419 women were randomized to one of four treatments: once-daily 1 mg E2V/2.5 mg MPA (1 + 2.

Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses.

Objective: To establish the long-term safety profile of four oestradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) regimens.

Study Design: 419 postmenopausal women in parallel treatment groups started treatment with 1 or 2 mg E(2)V with either 2.5 or 5 mg MPA for 84 cycles of 28 days in a randomised, comparative study.